Gang Wu, M.D

CONTACT

Lead Sponsor

Gang Wu

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Age \> 18 years old, male and female;
•2. According to the Guidelines for the Diagnosis and Treatment of Primary Lung Cancer (2022 edition), the patient was diagnosed with NSCLC by imaging and histopathology;
•3. TNM stages were III-IV;
•4. Newly diagnosed, first-line treatment failure, refusal or inability to perform conventional treatment (surgery, chemoradiotherapy);
•5. ECOG PS ≤2;
•6. Expected survival \> 3 months;
•7. Sign the informed consent voluntarily, and the compliance is good.

•1. Previously received interventional therapy (iodine particle implantation, ablation, TACE treatment);
•2. Combined with extensive and uncontrolled extrapulmonary metastases, such as liver metastasis, bone metastasis, and brain metastasis;
•3. Have had or currently having other primary malignant tumors;
•4. White blood cell \< 3×109/L, platelet count \< 50×109/L, HGB \< 90 g/L;
•5. Hepatic and renal insufficiency (creatinine \> 2 mg/L; AST and/or ALT \> 2 times the normal upper limit);
•6. Coagulation dysfunction (INR \> 1.5) or known bleeding disease (except lung cancer combined with hemoptysis), or anticoagulation therapy;
•7. Patients with active infection requiring antibiotic treatment;
•8. Uncontrolled hypertension, diabetes, and cardiovascular disease with obvious symptoms;
•9. contrast agent allergy;
•10. Women with pregnancy or lactation.

Related studies

NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more

NCT06549816 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more

NCT02098954 · Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation

NCT04151563 · Carcinoma, Non-small Cell Lung Cancer

NCT03232593 · Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, and more

Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC